|
Arcturus Therapeutics Holdings Inc. (ARCT) DCF Avaliação
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Arcturus Therapeutics Holdings Inc. (ARCT) Bundle
Projetado para precisão, nossa calculadora DCF (ARCT) permite avaliar a avaliação Arcturus Therapeutics Holdings Inc. usando dados financeiros do mundo real, fornecendo flexibilidade completa para modificar todos os parâmetros essenciais para projeções aprimoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8 | 9.5 | 12.4 | 205.8 | 157.7 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Revenue Growth, % | 0 | -54.12 | 29.56 | 1564.82 | -23.33 | 13.03 | 13.03 | 13.03 | 13.03 | 13.03 |
| EBITDA | -24.4 | -70.6 | -201.7 | 13.7 | -24.2 | -110.1 | -124.4 | -140.6 | -158.9 | -179.6 |
| EBITDA, % | -117.47 | -740.56 | -1631.68 | 6.66 | -15.32 | -61.73 | -61.73 | -61.73 | -61.73 | -61.73 |
| Depreciation | .7 | .9 | 1.2 | 1.5 | 3.0 | 8.8 | 10.0 | 11.3 | 12.8 | 14.4 |
| Depreciation, % | 3.29 | 9.25 | 9.65 | 0.74214 | 1.87 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 |
| EBIT | -25.1 | -71.5 | -202.9 | 12.2 | -27.1 | -111.0 | -125.5 | -141.8 | -160.3 | -181.2 |
| EBIT, % | -120.76 | -749.81 | -1641.33 | 5.92 | -17.19 | -62.26 | -62.26 | -62.26 | -62.26 | -62.26 |
| Total Cash | 71.4 | 462.9 | 370.5 | 391.9 | 292.0 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.2 | 2.1 | 3.4 | 2.8 | 32.1 | 29.1 | 32.9 | 37.2 | 42.1 | 47.5 |
| Account Receivables, % | 10.48 | 22.28 | 27.24 | 1.34 | 20.33 | 16.33 | 16.33 | 16.33 | 16.33 | 16.33 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0.00000809127 | 0 | 0 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 |
| Accounts Payable | 5.8 | 10.8 | 10.1 | 7.4 | 5.3 | 77.1 | 87.1 | 98.5 | 111.3 | 125.8 |
| Accounts Payable, % | 27.87 | 112.95 | 81.38 | 3.62 | 3.35 | 43.24 | 43.24 | 43.24 | 43.24 | 43.24 |
| Capital Expenditure | -.8 | -1.7 | -3.4 | -7.7 | -2.9 | -19.7 | -22.3 | -25.2 | -28.5 | -32.2 |
| Capital Expenditure, % | -3.93 | -18.26 | -27.56 | -3.75 | -1.84 | -11.07 | -11.07 | -11.07 | -11.07 | -11.07 |
| Tax Rate, % | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 |
| EBITAT | -24.8 | -70.7 | -206.0 | 10.7 | -28.9 | -107.8 | -121.9 | -137.8 | -155.7 | -176.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -21.4 | -66.6 | -210.2 | 2.5 | -60.3 | -44.0 | -127.9 | -144.6 | -163.4 | -184.7 |
| WACC, % | 15.61 | 15.61 | 15.61 | 15.58 | 15.61 | 15.61 | 15.61 | 15.61 | 15.61 | 15.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -408.3 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -192 | |||||||||
| Terminal Value | -1,655 | |||||||||
| Present Terminal Value | -802 | |||||||||
| Enterprise Value | -1,210 | |||||||||
| Net Debt | -262 | |||||||||
| Equity Value | -948 | |||||||||
| Diluted Shares Outstanding, MM | 27 | |||||||||
| Equity Value Per Share | -35.61 |
What You Will Get
- Real ARCT Financial Data: Pre-filled with Arcturus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Arcturus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Arcturus Therapeutics' historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: View Arcturus’ intrinsic value recalibrated instantly.
- Intuitive Visual Outputs: Dashboard charts showcase valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Arcturus Therapeutics Holdings Inc. (ARCT) preloaded data.
- 2. Adjust Key Inputs: Modify essential assumptions such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to bolster your strategic decisions.
Why Choose Arcturus Therapeutics Holdings Inc. (ARCT)?
- Innovative Solutions: Cutting-edge technology in RNA medicines tailored for unmet medical needs.
- Robust Pipeline: A diverse range of therapeutic candidates targeting various diseases.
- Expert Team: Led by industry veterans with extensive experience in biotech and pharmaceuticals.
- Strong Partnerships: Collaborations with leading organizations to enhance research and development.
- Commitment to Quality: Adherence to the highest standards in manufacturing and clinical trials.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced therapeutic models into academic projects or studies.
- Investors: Evaluate your investment strategies and analyze valuation outcomes for Arcturus Therapeutics Holdings Inc. (ARCT).
- Market Analysts: Enhance your analysis with a tailored, ready-to-use financial model specific to the biotech sector.
- Healthcare Entrepreneurs: Understand the methodologies used to assess large biotech firms like Arcturus Therapeutics Holdings Inc. (ARCT).
What the Template Contains
- Pre-Filled DCF Model: Arcturus Therapeutics' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Arcturus Therapeutics' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.